CymitQuimica logo

CAS 38821-49-7

:

Carbidopa monohydrate

Description:
Carbidopa monohydrate is a pharmaceutical compound primarily used in the treatment of Parkinson's disease and its symptoms. It functions as a dopa decarboxylase inhibitor, which prevents the conversion of levodopa to dopamine in the peripheral tissues, thereby increasing the availability of levodopa to the brain. This enhances the therapeutic effects of levodopa while minimizing side effects associated with peripheral dopamine production. The monohydrate form indicates that the compound contains one molecule of water for each molecule of carbidopa, which can influence its solubility and stability. Carbidopa monohydrate is typically administered in combination with levodopa to optimize treatment outcomes. It is characterized by its white to off-white crystalline appearance and is soluble in water, which facilitates its formulation in oral dosage forms. The compound is generally well-tolerated, although it may cause side effects such as nausea, dizziness, and dyskinesia in some patients. Overall, carbidopa monohydrate plays a crucial role in managing Parkinson's disease by enhancing the efficacy of levodopa therapy.
Formula:C10H14N2O4·H2O
InChI:InChI=1S/C10H14N2O4.H2O/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6;/h2-4,12-14H,5,11H2,1H3,(H,15,16);1H2/t10-;/m0./s1
InChI key:InChIKey=QTAOMKOIBXZKND-PPHPATTJSA-N
SMILES:[C@@](CC1=CC(O)=C(O)C=C1)(C(O)=O)(NN)C.O
Synonyms:
  • (+)-2-(3,4-Dihydroxybenzyl)-2-Hydrazinopropionic Acid Monohydrate
  • 3-(3,4-Dihydroxyphenyl)-2-Hydrazinyl-2-Methylpropanoic Acid Hydrate (1:1)
  • Benzenepropanoic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, monohydrate, (S)-
  • Benzenepropanoic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, monohydrate, (αS)-
  • Benzenepropanoic acid, α-hydrazinyl-3,4-dihydroxy-α-methyl-, hydrate (1:1), (αS)-
  • Carbidopa monohydrate
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 18 products.